Director/PDMR Shareholding

RNS Number : 6740X

Surgical Innovations Group PLC

17 February 2012

 



17 February 2012

Surgical Innovations Group plc

("SI" or the "Company")

Directors' Dealings

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that it received notification today on Friday 17 February 2012 Graham Bowland, Chief Executive Officer of the Company, sold 5,889,000 shares at price of 10.5 pence per share.

Following the sale, Graham Bowland is interested in 4,528,498 common shares representing approximately 1.12% of the common shares in issue, and also holds options over 1,400,000 shares.

The sale has been undertaken as a one off transaction for personal reasons, to enable Graham Bowland to make a property purchase.  Graham continues to be a significant holder in the Company, and his long term commitment to the business remains unchanged.

- Ends -

Enquiries:

Surgical Innovations Group plc	www.sigroupplc.com
Doug Liversidge, Non-Executive Chairman
Graham Bowland, Chief Executive Officer	Tel: [phone] or [e-mail]
Seymour Pierce Limited	www.seymourpierce.com
Freddy Crossley / Sarah Jacobs	Tel: [phone]
Corporate Broking
David Banks/ Jacqui Briscoe
Walbrook PR Ltd	Tel: [phone]
Paul McManus	Mob: [phone] or [e-mail]
Fiona Henson	Mob: [phone] or [e-mail]

Notes to Editors:

About Surgical Innovations Group plc

Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery (MIS) and industrial markets. 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

Over 100 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

The Group's patented products are sold through three main channels:

SI brand	Through an established network of 45 distribution partners, Surgical Innovations branded products are sold in all major medical markets including North America, Europe, South Africa, the Middle East, South-east Asia and Australia.
OEM and IP	The Group supplies large medical device companies on an OEM basis, collecting sales fees as well as IP license and royalty fees.  Clients include Teleflex Medical, Gyrus and CareFusion.
Industrial	SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, such as turbines, in situ with minimum disassembly and downtime.

For more information, see www.surginno.com

 

END

 

 

RDSBLGDDSXBBGDR